Business
Commercial Real Estate Index
Sherwood News

Return-to-office orders might not be enough to save commercial real estate from more pain

Workers at banks like JPMorgan are considering unionizing to push back on office attendance.

Working from home, alongside hygiene practices and viral recipes, is one of few positive social effects from the pandemic. Now, though, some companies are acting ASAP on RTO mandates to eradicate WFH.

Remote control

At the end of last week, JPMorgan Chase told employees that it would enforce a five-day in-office mandate, sparking a companywide pushback against the perceived infringement on work-life balance… even inspiring some employees to evaluate forming a workers’ union, Barron’s reported.

JPMorgan isn’t the first industry titan to lay down the law on full-time office attendance, with Goldman Sachs and Amazon already tightening their rules, but the internal response indicates an ongoing sentiment in America: many just don’t want to go back to their desks full time.

Office vacancies hit another record high at the end of last year, according to the latest tally from Moody’s, with ~20.4% of office space in the top 50 US metro areas now estimated to be empty.

Vested interests

One group watching the commuter crawl-back trend with interest: commercial real estate (CRE) investors. The latest data from FRED shows that CRE prices were down 12.5% since early 2023.

Although that’s not yet anywhere near as bad as the two most recent CRE crashes in the US — when values fell by ~17% (1989-1993) and ~35% (2007-2010), respectively — if swathes of workers continue to rebuff RTO instructions, the market could come under further pressure. Eventually, collapsing office loans could result in traditional corporate hubs like NYC’s Financial District being adapted into residential or retail properties to recover some of the losses incurred.

TL/DR: America doesn't need as much office space as it used to... how much less still isn’t clear — but there’s a lot at stake for employers, employees (particularly unionized ones), and investors.

More Business

See all Business
business

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration. 

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Hims oral semaglutide

Hims, long flying under regulators’ radar, finally strikes a nerve with its Wegovy pill copy

It’s unclear if the pill Hims is selling works or if the FDA will allow it.

$1.3M

There’s still plenty of money to be made in brainrot. The top 1,000 Roblox creators earned an average of $1.3 million in 2025 — up 50% from the year prior — according to CEO Dave Baszucki on the company’s fourth-quarter earnings call.

Roblox paid out $1.5 billion to creators last year, meaning its top 1,000 creators took home about 87% of the total pool.

Like other creator economy giants, Roblox rewards its biggest creators for their contributions to user engagement. Creator-made titles like “Grow a Garden” and “Steal a Brainrot” substantially boosted playing time over the course of the year. In September, the company increased its developer exchange rate, or the ratio of in-game currency to cash payout, by 8.5%.

Texas Governor Abbott And Google Make Economic Development Announcement In Midlothian

Alphabet could buy some pretty huge businesses with the amount of money it plans to spend this year

AI outlays have gone full nut-nut. Even Google, one of the most capital-efficient businesses of all time in its heyday, is spending like there’s no tomorrow.

Tom Jones2/6/26

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.